Picture loading failed.

Anti-CD40LG therapeutic antibody (Pre-made Ruplizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ruplizumab (trade name Antova) is a humanized monoclonal antibody intended for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis. A study showed that the drug was associated with life-threatening thromboembolisms, while another study only found thrombocytopenia.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-501-1mg 1mg 3090
GMP-Bios-ab-501-10mg 10mg 21890
GMP-Bios-ab-501-100mg 100mg 148000
GMP-Bios-ab-501-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD40LG therapeutic antibody (Pre-made Ruplizumab biosimilar,Whole mAb)
INN Name Ruplizumab
TargetCD40LG
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI Structure1i9r:HL:KM:XY
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2000
Year Recommended2001
CompaniesBiogen
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAutoimmune disorders;Haemophilia A;Idiopathic thrombocytopenic purpura;Multiple sclerosis;Renal transplant rejection;Systemic lupus erythematosus
Development Techna